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Abstract
Objective: Due to its anti-oxidant and anti-inflammatory properties, bilirubin has been associated with reduced
cardiovascular risk. A recent study demonstrated an L-shaped association of pre-treatment total bilirubin levels with total
mortality in a statin-treated cohort. We therefore investigated the association of total bilirubin levels with total mortality in a
nationally representative sample of older adults from the general population.
Methods: A total of 4,303 participants aged $60 years from the United States National Health and Nutrition Examination
Survey 1999–2004 with mortality data followed up through December 31, 2006 were included in this analysis, with a mean
follow-up period of 4.5 years.
Results: Participants with total bilirubin levels of 0.1–0.4 mg/dl had the highest mortality rate (19.8%). Compared with
participants with total bilirubin levels of 0.5–0.7 mg/dl and in a multivariable regression model, a lower total bilirubin level
of 0.1–0.4 mg/dl was associated with higher risk of total mortality (hazard ratios, 1.36; 95% confidence interval, 1.07–1.72;
P = 0.012), while higher levels ($0.8 mg/dl) also tended to be associated with higher risk of total mortality, but this did not
reach statistical significance (hazard ratios, 1.24; 95% confidence interval, 0.98–1.56; P = 0.072).
Conclusion: In this nationally representative sample of older adults, the association of total bilirubin levels with total
mortality was the highest among those with a level between 0.1 and 0.4 mg/dl. Further studies are needed to investigate
whether higher total bilirubin levels could be associated with a higher mortality risk, compared to a level of 0.5–0.7 mg/dl.
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Introduction
Bilirubin is produced by the action of the enzyme biliverdin
reductase on biliverdin during the degradation of heme [1]. Heme
oxygenase (HO), the rate-limiting enzyme in the degradation of
heme to biliverdin, carbon monoxide and ferritin, has been
suggested as a potential therapeutic target in vascular diseases [1–
3]. For example, HO-1, the inducible isoform of HO, plays a role
in vascular repair by increasing circulating endothelial progenitor
cells [4]. Induction of HO-1 expression can also improve vascular
dysfunction in animal models of atherosclerosis, thrombosis,
myocardial infarction, and hypertension [3].
Notably, bilirubin has anti-oxidant and anti-inflammatory
effects, and can protect serum lipids from oxidation [1]. In this
regard, previous studies have suggested bilirubin to be a protective
biomarker for cardiovascular risk [1]. For example, lower total
bilirubin levels are associated with higher risk of the metabolic
syndrome [5], coronary artery disease (CAD) [6], peripheral
arterial disease [7], stroke [8], and other cardiovascular diseases
(CVDs) [1]. Higher total bilirubin levels (within the normal range)
are also associated with a lower risk of cancer [9] and decreased
cancer mortality [10]. Among patients from primary care
practices, higher total bilirubin levels are also associated with a
lower risk of respiratory diseases and total mortality [11].
In a recent prospective study of a large, statin-treated cohort,
total bilirubin levels measured 3 months before statin treatment
were found to be associated with any CVD event, coronary heart
disease, myocardial infarction, and all-cause mortality in a non-
linear and L-shaped relationship [12]. However, it is not known
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whether such non-linear L-shaped associations are apparent in a
nationally representative sample of the general population.
Moreover, there is a lack of studies on this association in older
adults, who are at a high mortality risk due to aging. We therefore
examined the association of total bilirubin levels with total
mortality in older adults using data from the US National Health
and Nutrition Examination Survey (NHANES). We also investi-
gated whether such associations differed by demographic and
lifestyle factors that were associated with total bilirubin levels.
Subjects and Methods
Study subjects
NHANES was conducted by the National Center for Health
Statistics of the Centers for Disease Control and Prevention as a
continuous cross-sectional survey of the health and nutritional
status of the civilian, non-institutionalized United States popula-
tion [13]. In 1999, the survey became a continuous program and
examined a nationally representative sample of about 5,000 people
each year. Data were released for every two-year cycle. The
detailed measurement procedures and protocols have been
described elsewhere [13]. All participants gave informed consent
and the study received approval from the Centers for Disease
Control and Prevention Institutional Review Board.
In NHANES 1999–2004 there were 4,984 participants aged
$60 years who were both interviewed and examined in the mobile
examination center. As total bilirubin levels are often elevated in
liver diseases, 678 subjects with abnormal liver function (defined as
a serum aspartate aminotransferase or alanine aminotransferase
.100 U/l, a serum c-glutamyltransferase .100 U/l, or total
bilirubin level.3 mg/dl) [14,15], or a self-reported history of liver
diseases were excluded from the analysis to avoid the confounding
effect of liver diseases, including those with subclinical and
undiagnosed diseases. Among the remaining 4,306 participants,
4,303 participants had mortality data followed up through
December 31, 2006 with a mean follow-up period of 4.5 years
(range 0 to 92 months).
Variables of interest
Mortality information was based on the results from a
probabilistic match between NHANES and National Death Index
death certificate records [16]. The causes of death were grouped
into a standardized list of 113 causes based on the International
Classification of Diseases, Tenth Revision (ICD-10). This allowed
the number of deaths from CVDs (ICD-10 codes I00-I78 and I80-
I99), cancer (ICD-10 codes C00–D48), and liver disease (ICD-10
codes B15-B19, K70, and K73-K74) to be estimated. Briefly, total
bilirubin levels were measured as part of the routine liver function
test using an Hitachi Model 704 multichannel analyzer (Boehrin-
ger Mannheim Diagnostics, Indianapolis, IN) in 1999–2000, a
Beckman Synchron LX20 system in 2003–2007 and a Beckman
Synchron DxC800 system (Beckman Coulter Inc, Fullerton, CA)
in 2008–2010. In 2001–2002, these levels were measured using
either an Hitachi Model 704 multichannel analyzer or a Beckman
Synchron LX20 system. The reported values have been adjusted
by regression equations to allow comparison across the two
methods [13].
Other covariates
Information on race/ethnicity, education, smoking, alcohol
consumption, medications for hypertension and diabetes, history
of CVD (defined as heart attack, congestive heart failure, coronary
heart disease, angina, or stroke), arthritis and cancer were
obtained from self-reported questionnaires at baseline. Body mass
index (BMI) was calculated as weight in kilograms divided by the
square of height in meters. Ever smokers were defined as subjects
who had smoked $100 cigarettes in their lives. Regular alcohol
consumption was defined as consumption of any type of alcoholic
beverage at least once a week in the past year. Hypertension was
defined as blood pressure $140/90 mm Hg or taking anti-
hypertensive medications. Diabetes was defined as a history of
physician diagnosis, non-fasting glucose $200 mg/dl, glycated
hemoglobin $6.5%, or being treated with insulin or oral glucose-
lowering medications. Data on the usage of different classes of
lipid-lowering medication (including statins, fibrates, nicotinic
acid, and other classes) and anti-hypertensive medication (includ-
ing angiotensin-converting enzyme inhibitors [ACEI]/angiotensin
receptor blockers [ARB], diuretics, b-blockers, calcium channel
blockers [CCB], and others) in the past month were obtained from
questionnaires of prescription medications as described [15,17,18].
The estimated glomerular filtration rate (eGFR) was calculated
using the modified prediction equation from the Modification of
Diet in Renal Disease study [19]. Albuminuria was defined as a
urinary albumin-to-creatinine ratio $30 mg/mg [20]. Total white
blood cell counts and hemoglobin levels were determined using the
Beckman Coulter MAXM instrument (Beckman Coulter Inc,
Fullerton, CA). Details on the laboratory analytical methods of
other clinical biochemical parameters have been described
previously [13,15,17,18].
Statistical analysis
Data analysis was performed using the complex sampling
function of SPSS version 21.0 (SPSS Inc, Chicago, IL). Data are
expressed as mean, percent (standard error), or geometric mean
(95% confidence interval [CI]). All variables had less than 5%
missing data (Supplementary Table S1). To obtain estimates
representative of the United States Census civilian non-institu-
tionalized population, examination sampling weights were used in
all analyses to adjust for non-response bias and the oversampling
of blacks and Mexican Americans [13]. Sampling errors were
estimated using the primary sampling units and strata provided in
the dataset.
Cox proportional hazards regression was used to estimate the
hazard ratios (HR) for total mortality. As most participants
(n = 952) had a total bilirubin level of 0.6 mg/dl (i.e. 10 mmol/l),
this level was used as the referent group for comparison in the
initial analysis (multicategory model A). In the recent study of
Horsfall et al [12], total bilirubin level was transformed into
restricted cubic spines with 4 knots at 0.3 mg/dl (5 mmol/l),
0.5 mg/dl (9 mmol/l), 0.7 mg/dl (12 mmol/l), and 1.2 mg/dl
(20 mmol/l) [12]. Therefore in a separate analysis (multicategory
model B), we divided the subjects into 3 groups (0.1–0.4, 0.5–0.7
and $0.8 mg/dl as the number of subjects ,0.3 and .1.2 are
small (n = 38 and 172 respectively). To account for the variations
that may be due to changes in measurement sites and methods, the
survey year was included in the regression model as a categorical
independent variable. Age, sex, race/ethnicity, body mass index,
and other variables, that showed significant difference between
participants who were alive and those who were decreased (i.e.
those with P,0.05 in Table 1) or correlated with total bilirubin
levels (i.e. those with P,0.05 in Supplementary Table S1) were
used as covariates in the Cox regression analysis. No multi-
collinearity issue was detected as assessed by the variance inflation
factors (,3.0 for all covariates). The P values for interaction were
estimated by including each multiplicative interaction term in the
regression models in full sample after adjusting for the main effects
of the covariates. To assess the potential non-linear U-shaped
relationship between total bilirubin and total mortality, total
Bilirubin; Mortality; NHANES; Older Adults
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Table 1. Clinical Characteristics in United States Older Adults by Mortality Status, 1999–2004.
Characteristics Alive (n =3603) Deceased (n=700) Pc
Demographic and lifestyle factors
Age, y 70.3 (0.2) 76.2 (0.4) ,0.001
Women, % 58.3 (0.8) 48.1 (2.3) ,0.001
BMI, kg/m2 28.4 (0.1) 27.1 (0.3) 0.12
Race/ethnicity, % 0.007
Non-Hispanic White 81.8 (1.8) 82.5 (2.3)
Non-Hispanic Black 7.4 (1.0) 9.7 (1.6)
Mexican American 3.2 (0.8) 2.4 (0.6)
Others 7.6 (1.2) 5.5 (1.6)
Education, % ,0.001
,High school 28.4 (1.5) 38.8 (2.1)
High school diploma 28.9 (1.1) 29.6 (2.1)
.High school 42.7 (1.4) 31.7 (2.8)
Smoking, % ,0.001
Never 48.2 (1.2) 39.4 (2.2)
Former 41.3 (1.1) 43.0 (2.0)
Current 10.5 (0.6) 17.5 (2.4)
Regular alcohol consumption, % 26.5 (1.7) 19.3 (1.7) 0.005
Chronic conditions
History of CVD, % 20.9 (1.0) 42.5 (2.1) ,0.001
Diabetes, % 17.7 (1.0) 20.5 (1.6) 0.034
Hypertension, % 65.5 (1.1) 72.4 (2.0) 0.39
Albuminuria,% 17.0 (0.8) 40.4 (2.3) ,0.001
Arthritis, % 49.2 (1.0) 52.9 (2.3) 0.28
Cancer, % 19.8 (0.7) 28.6 (1.9) 0.007
Lipid-lowering medication, % 27.1 (0.9) 22.0 (2.2) 0.50
Statin 25.1 (0.8) 19.0 (2.1) 0.19
Fibrate 1.7 (0.2) 2.7 (0.8)d 0.011
Nicotinic acid 0.4 (0.1) 0.8 (0.5)d 0.68
Othersa 1.3 (0.3) 0.2 (0.2)d 0.15
Anti-hypertensive medication, % 54.8 (1.3) 66.7 (2.4) 0.002
ACEI/ARB 28.0 (1.3) 30.6 (1.8) 0.002
Diuretic 24.6 (1.0) 33.7 (2.4) 0.019
b-blocker 18.5 (0.8) 21.4 (2.2) 0.052
CCB 17.7 (0.7) 24.2 (1.7) 0.11
Others 9.9 (0.6) 16.9 (2.1) 0.002
Clinical biomarkers
Total cholesterol, mg/dl 211.2 (0.8) 209.1 (2.1) 0.63
HDL cholesterol, mg/dl 54.4 (0.5) 53.5 (0.7) 0.96
Serum albumin, g/dl 4.24 (0.01) 4.16 (0.02) ,0.001
Blood urea nitrogen, mg/dlb 15.3 (15.0–15.6) 18.5 (17.8–19.2) ,0.001
eGFR, ml/min/1.73 m2 71.2 (0.5) 62.7 (1.0) ,0.001
C-reactive protein, mg/dlb 0.25 (0.24–0.26) 0.35 (0.32–0.38) ,0.001
Alkaline phosphatase, U/lb 70.8 (69.7–72.0) 76.3 (74.3–78.3) 0.002
Alanine aminotransferase, U/lb 20.3 (19.9–20.7) 17.8 (17.2–18.4) ,0.001
Aspartate aminotransferase, U/lb 22.9 (22.6–23.2) 22.6 (22.0–23.2) 0.51
c-glutamyltransferase, U/lb 21.5 (20.9–22.1) 21.6 (20.7–22.6) 0.026
Uric acid, mg/dl 5.59 (0.03) 6.08 (0.09) ,0.001
White blood cell count, 103cells/mlb 6.78 (6.69–6.87) 7.31 (7.08–7.55) ,0.001
Bilirubin; Mortality; NHANES; Older Adults
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bilirubin values were entered as both a linear and quadratic terms
at the same time in the Cox regression model and after full
adjustment [21]. A two-tailed P,0.05 was considered statistically
significant.
Results
Among the 4,303 participants, there were 700 deaths identified
with a weighted mortality rate of 14.2% over a mean follow-up
period of 4.5 years. Cause of death was identified in 692 of 700
subjects, with 270 deaths from CVD, 169 deaths from cancer and
253 deaths from other causes (including 3 deaths from liver
disease). Table 1 shows the baseline characteristics of the
participants according to the mortality status. Compared to
participants who were alive, those who were deceased were more
likely to be older, male, non-Hispanic Black, less educated, current
smokers, and not regular alcoholic drinkers, with higher preva-
lence of CVD, diabetes, albuminuria, and cancer. They were also
more likely to take anti-hypertensive medications, especially
ACEI/ARB and diuretics, and have higher blood urea nitrogen,
C-reactive protein, alkaline phosphatase, c-glutamyltransferase,
uric acid and white blood cell count, and lower serum albumin,
eGFR, alanine aminotransferase and hemoglobin levels.
Supplementary Table S1 shows the clinical characteristics when
total bilirubin levels were divided into six categories with similar
numbers of participants. Participants with lower total bilirubin
levels were younger, female, non-Hispanic Black, current smokers,
and not regular alcohol drinkers; they also had a higher prevalence
of diabetes, with lower serum albumin, alanine aminotransferase,
aspartate aminotransferase, uric acid and hemoglobin levels, but
higher levels of high-density lipoprotein (HDL) cholesterol, C-
reactive protein, alkaline phosphatase and total white blood cell
counts. The prevalence of self-reported CVD also tended to
decrease with higher total bilirubin, although the highest
prevalence was found in participants with a total bilirubin level
of $1.0 mg/dl. Participants with higher total bilirubin levels
tended to take lipid-lowering medications such as statins, but the
differences did not reach statistical significance. They were less
likely to take CCB.
Table 2 shows the total mortality rates in participants according
to six different categorical groups of total bilirubin levels. The
highest mortality rate was found in participants with total bilirubin
levels of 0.1–0.4 mg/dl, although there was no significant
difference in baseline total bilirubin levels between participants
who were alive and those who were deceased (P = 0.078, Table 1).
In the multivariable Cox regression model, a total bilirubin level of
0.1–0.4 mg/dl was associated with a higher risk of total mortality,
compared to a level of 0.6 mg/dl after adjusting for confounding
factors (P = 0.014, multicategory model A, Table 3). Compared to
a level of 0.6 mg/dl, a total bilirubin of$0.8 mg/dl also tended to
be associated with a higher risk of total mortality, although the
association did not reach statistical significance. Similar results
were obtained in the Cox regression analysis when total bilirubin
levels were divided into three groups, 0.1–0.4, 0.5–0.7 and
$0.8 mg/dl (multicategory model B, Table 3).
Figure 1 shows the adjusted cumulative survival curves. The
survival curves of the total bilirubin levels of 0.1–0.4 mg/dl and
$0.8 mg/dl diverged from that of a level of 0.5–0.7 mg/dl
throughout the follow-up period without overlapping. In a test for
the non-linear U-shaped relationship fitting a linear and quadratic
terms of total bilirubin, a trend of U-shaped relationship was
suggested by a marginal non-significant P value for the quadratic
term (P= 0.066). In the analysis with cause-specific mortality
(Supplementary Table S2), compared to a level of 0.5–0.7 mg/dl
total bilirubin, a total bilirubin level of 0.1–0.4 mg/dl tended to be
associated with higher cancer mortality (HR, 1.94; P = 0.016),
whereas a total bilirubin level of $0.8 mg/dl tended to be
associated more with mortality unrelated to CVD and cancer (HR,
1.88; P= 0.002).
A significant interaction between race/ethnicity and total
bilirubin levels was found for total mortality (P for interac-
tion= 0.008). In non-Hispanic Whites, both lower and higher
levels of total bilirubin were significantly associated with a higher
mortality risk (Table 4). There was also a significant interaction
between smoking and total bilirubin levels for total mortality (P for
interaction= 0.047). Among current smokers, a more linear
association was found, in which lower total bilirubin levels were
associated with higher mortality risk, and higher levels were
associated with lower risk (Table 4). Among never smokers, higher
Table 2. Percentages of Total Death in United States Older
Adults, 1999–2004.
Total bilirubin, mg/dl Number at riska Total death
Numbera % (SE)
0.1–0.4 605 129 19.8 (1.6)
0.5 655 130 15.6 (1.5)
0.6 952 137 12.6 (1.2)
0.7 669 97 12.8 (1.8)
0.8–0.9 832 125 13.4 (1.3)
$1.0 590 82 12.3 (1.4)
SE = standard error.
aUnweighted numbers.
doi:10.1371/journal.pone.0094479.t002
Table 1. Cont.
Characteristics Alive (n =3603) Deceased (n=700) Pc
Hemoglobin, g/dl 14.3 (0.1) 13.9 (0.1) ,0.001
Total bilirubin, mg/dlb 0.66 (0.64–0.67) 0.62 (0.60–0.64) 0.078
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index; CCB = calcium channel blocker; CI = confidence
interval; CVD = cardiovascular disease; eGFR = estimated glomerular filtration rate; HDL = high-density lipoprotein; SE = standard error.
Data are expressed as mean or percent (standard error), unless otherwise noted.
aIncludes bile acid sequestrants, cholesterol adsorption inhibitors, and other types of lipid-lowering medications.
bData are expressed as geometric mean (95% CI).
cEstimated from the Cox regression model after adjusted for age, sex, race/ethnicity, and survey period, where appropriate.
dEstimates are unreliable due to coefficient of variation . 0.3.
doi:10.1371/journal.pone.0094479.t001
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levels of total bilirubin were more strongly associated with higher
risk of total mortality than lower levels of total bilirubin. No
significant interaction was found for age, gender and alcohol
drinking (Supplementary Table S3). As shown in Supplementary
Table S4, non-Hispanic Whites tended to have the highest
prevalence of self-reported CVD and usage of lipid-lowering
medications.
Discussion
This study investigated the relationship between total bilirubin
levels and total mortality after a mean follow-up period of 4.5
years in a national representative population of older men and
women. The results show that the association of total bilirubin
levels with total mortality was non-linear, which is consistent with
a previous report by Horsfall et al [12]. In both studies, low total
bilirubin levels were significantly associated with a higher mortality
risk. Of note, there was also a tendency for a total bilirubin level of
$0.8 mg/dl to be associated with a higher mortality risk,
compared to a level of 0.5–0.7 mg/dl in the present study,
especially in non-Hispanic Whites and never smokers.
The association of lower total bilirubin levels with higher total
mortality risk is expected as bilirubin has anti-oxidant and anti-
inflammatory effects [1]. This is consistent with other previous
studies [10–12]. Genetic variants associated with higher total
bilirubin levels have been shown to be associated with lower risk of
total mortality, suggesting a causal relationship between total
bilirubin and mortality risk [22]. In the recent study of Horsfall et
al, lower total bilirubin levels were associated with a higher risk of
any CVD event, coronary heart disease, myocardial infarction,
and all-cause mortality [12]. An inverse relationship between total
bilirubin and CVD mortality has also been reported [23].
However, in our present study, we did not observe any significant
association of lower total bilirubin levels with higher risk of CVD
mortality. In this regard, conflicting results on the relationship
between total bilirubin and CVD have been reported. A recent
study of 43,708 people in Denmark demonstrated that the inverse
association of total bilirubin with ischemic heart disease and
Table 3. Association of Total Bilirubin Levels With Total Mortality in United States Older Adults, 1999–2004.
Total bilirubin, mg/dl Model 1
a Model 2b Model 3c Model 4d
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Multicategory model A
0.1–0.4 1.57 (1.14–2.16) 0.007 1.53 (1.06–2.20) 0.024 1.68 (1.21–2.32) 0.002 1.51 (1.09–2.09) 0.014
0.5 1.33 (0.98–1.79) 0.063 1.13 (0.81–1.59) 0.45 1.18 (0.83–1.68) 0.34 1.19 (0.85–1.68) 0.31
0.6 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
0.7 1.03 (0.80–1.33) 0.81 1.05 (0.79–1.39) 0.73 1.06 (0.76–1.49) 0.73 1.18 (0.86–1.61) 0.30
0.8–0.9 1.09 (0.86–1.38) 0.46 1.16 (0.90–1.50) 0.25 1.18 (0.87–1.59) 0.27 1.35 (1.00–1.83) 0.051
$1.0 0.98 (0.69–1.39) 0.90 1.20 (0.84–1.73) 0.31 1.18 (0.80–1.73) 0.40 1.38 (0.98–1.94) 0.061
Overall P 0.10 0.14 0.013 0.022
Multicategory model B
0.1–0.4 1.39 (1.09–1.78) 0.010 1.44 (1.10–1.88) 0.009 1.55 (1.23–1.96) ,0.001 1.36 (1.07–1.72) 0.012
0.5–0.7 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
$0.8 0.96 (0.79–1.18) 0.70 1.12 (0.91–1.39) 0.28 1.11 (0.89–1.37) 0.36 1.24 (0.98–1.56) 0.072
Overall P 0.030 0.031 0.002 0.008
HR = hazard ratio; CI = confidence interval.
aAdjusted for survey period, age, sex, and race/ethnicity (n = 4,303).
bFurther adjusted for body mass index, education, smoking, and regular alcohol consumption (n = 3,928).
cFurther adjusted for history of cardiovascular disease, diabetes, albuminuria, cancer, fibrates, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers,
diuretics, and calcium channel blockers (n = 3,764).
dFurther adjusted for high-density lipoprotein cholesterol, serum albumin, blood urea nitrogen, estimated glomerular filtration rate, C-reactive protein, alkaline
phosphatase, alanine aminotransferase, aspartate aminotransferase, c-glutamyltransferase, uric acid, white blood cell count, and hemoglobin (n = 3,758).
doi:10.1371/journal.pone.0094479.t003
Figure 1. The cumulative survival curve for total mortality from
the Cox regression model after full adjustment (model 4 of
Table 3).
doi:10.1371/journal.pone.0094479.g001
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myocardial infarction becomes not significant after further
adjustment for more cardiovascular risk factors [24]. Meta-analysis
of studies involving 14,711 case and 60,324 controls also has not
revealed a causal relationship between total bilirubin and
cardiovascular diseases [24]. Another recent study has shown that
genetic variants, associated with total bilirubin levels, are
associated with total mortality, but not vascular calcified plaque
and CVD mortality [25]. The non-significant association between
total bilirubin and CVD mortality in that study and our present
study could be due to the low number of CVD deaths and thus
insufficient power. Nevertheless, our study suggests that lower
levels of total bilirubin may be more related to non-CVD
mortality, such as cancer mortality, than CVD mortality.
It is unclear why higher total bilirubin levels were associated
with higher mortality risk, especially in in non-Hispanic Whites
and never smokers in this study. It is interesting that some previous
studies have demonstrated an association of higher total bilirubin
levels with higher CVD and total mortality risk. For example, a
non-linear U-shaped relationship between total bilirubin levels and
risk of incident CAD has been reported in a previous study of 216
CAD patients and 434 matched controls with a 5-year follow-up
[26]. In the British Regional Heart Study, a prospectively study of
7,685 middle-aged British men with a 11.5 year of follow-up, a U-
shaped relationship between total bilirubin and ischemic heart
disease was also found [21]. In the Simvastatin and Ezetimibe in
Aortic Stenosis study, a randomized trial studying the effects of
simvastatin and ezetimibe therapy on cardiovascular adverse
events in 1,873 patients with mild-to-moderate, asymptomatic
aortic stenosis, higher total bilirubin levels were associated with
higher total mortality risk [27]. In another study of patients with
ST-elevation myocardial infarction (STEMI), high total bilirubin
levels were associated with higher risk of cardiovascular mortality,
advanced heart failure, and adverse cardiac events after primary
coronary intervention [28]. In fact, total bilirubin levels have been
reported to be elevated, probably due to an increase in stress-
induced HO-1 activity after acute myocardial infarction [29], and
total bilirubin levels are positively associated with the severity of
coronary artery disease in patients with both STEMI [30], and
non-STEMI [31]. Therefore, the association of high total bilirubin
levels with higher total mortality risk could be a reflection of stress-
induced activation of HO-1 increasing total bilirubin levels as a
protective mechanism.
Total bilirubin levels are often elevated in liver diseases and may
therefore contribute to the association with higher mortality risk.
However, it should be noted that participants with abnormal liver
function were excluded from the present study and that there were
only 3 deaths from liver disease (including viral hepatitis) among
the 692 participants with identified causes of death.
Another possible explanation for the association of higher total
bilirubin levels with higher mortality risk could be due the
confounding effect by indication, with the participants that had
been diagnosed with CVD being at increased risk of mortality
from CVD. That is, as participants with self-reported CVD are
likely to be taking lipid-lowering medications, especially statins, to
reduce cardiovascular events, they tended to have higher total
bilirubin levels as a consequence of statin-mediated stimulation of
HO-1 activity [32–34]. This hypothesis was supported, at least in
part, by the finding that the prevalence of self-reported history of
CVD was the highest in patients with the highest total bilirubin
levels. There was also a non-significant trend of higher usage of
lipid-lowering medication (mainly statins) with high bilirubin levels
(Supplementary Table S1). This confounding effect by indication
may also explain the stronger relationship of higher total bilirubin
levels with higher mortality risk in non-Hispanic Whites, who had
the highest prevalence of self-reported CVD and usage of lipid-
lowering medications (Supplementary Table S4). Notably, higher
levels of total bilirubin also tended to be associated with higher risk
of mortality not related to CVD and cancer. Further studies with
larger sample sizes are needed to elucidate the association of
higher total bilirubin levels with different cause-specific mortality
risk.
In a sub-group analysis, a more linear association of lower total
bilirubin levels with higher total mortality risk was found in current
smokers. A previous study of NHANES data has demonstrated a
stronger inverse association between total bilirubin and peripheral
arterial disease in current smokers than non-smokers [7]. As
smoking can increase inflammation and oxidative stress, it is
possible that bilirubin may offer more protection in smokers, than
Table 4. Associations of Lower and Higher Total Bilirubin Levels With Total Mortality by Race/ethnicity and Smoking Status in
United States Older Adults, 1999–2004.a
Subgroup n Mortality rate, % (SE) 0.1–0.4 mg/dl $0.8 mg/dl Overall P
HR (95% CI) P HR (95% CI) P
Race/ethnicity
Non-Hispanic White 2511 14.3 (1.0) 1.52 (1.145–2.03) 0.006 1.38 (1.06–1.80) 0.018 ,0.001
Non-Hispanic Black 655 17.8 (2.0) 1.13 (0.59–2.17) 0.71 1.17 (0.58–2.37) 0.66 0.86
Mexican American 879 10.8 (1.6) 1.11 (0.61–2.02) 0.74 0.46 (0.19–1.10) 0.081 0.21
Others 258 10.6 (1.8) 0.21 (0.02–1.82) 0.15 0.21 (0.02–2.85) 0.24 0.25
Smoking
Never 2024 12.0 (0.9) 1.28 (0.80–2.05) 0.29 1.62 (1.08–2.43) 0.020 0.048
Former 1765 14.7 (0.9) 0.98 (0.61–1.57) 0.93 1.22 (0.84–1.76) 0.29 0.52
Current 505 21.7 (2.8) 2.55 (1.39–4.67) 0.003 0.59 (0.25–1.41) 0.23 0.002
CI = confidence interval; HR = hazard ratio.
aParticipants with total bilirubin levels of 0.5–0.7 mg/dl were used as the referent group for comparison. All data were adjusted for survey period, age, sex, race/
ethnicity, body mass index, education, smoking, regular alcohol consumption, history of cardiovascular disease, diabetes, albuminuria, cancer, fibrates, angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers, diuretics, calcium channel blockers, high-density lipoprotein cholesterol, serum albumin, blood urea
nitrogen, estimated glomerular filtration rate, C-reactive protein, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, c-glutamyltransferase, uric
acid, white blood cell count, and hemoglobin.
doi:10.1371/journal.pone.0094479.t004
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non-smokers. In fact, total bilirubin levels are lower in smokers
and decrease with increasing smoking amount and duration
[9,35]. A recent study found a significant, positive association of
total bilirubin levels with lung function in smokers with high BMI,
but not in non-smokers [36].
The major limitations of this study include the small sample size,
the low number of deaths and the short follow-up period, all of
which limit the study power. This also makes the analysis of the
relationship of total bilirubin levels with cause-specific mortality,
other than CVD and cancer mortality, not feasible. Common
genetic variants, such as those in the gene encoding the hepatic
enzyme uridine diphosphate-glucuronosyltransferase 1 (UGT1A1),
have been shown to affect total bilirubin levels, and thus may
confound the results [1,22,24,25]. Despite these limitations, our
study has the advantage of using data from NHANES with an
appropriate sampling design, quality control, and nationally
representative estimates. The availability of data on different
covariates helps to minimize their confounding effect by adjust-
ment in multivariable regression model.
In conclusion, in this study of a national representative sample
of older adults from the general population, a non-linear
association was found between total bilirubin levels and total
mortality. Further studies are needed to elucidate potential
mechanism of this association.
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